High expression of a specific protein is associated with an improved 5-year survival rate of almost 28% in gastric cancer. READ MORE
Journal of Clinical Pathways provides highlights from the annual Gastrointestinal Cancers Symposium in San Francisco, California (January 19-21, 2017).
At the second annual Oncology Nurse Advisor Navigation Summit, Teresa Labovich, MSN, RN, OCN, described a method by which gastrointestinal (GI) oncology nurse navigators (ONN) can play a role in improving institutional efficiency and patient outcomes.
High expression of a specific protein is associated with an improved 5-year survival rate of almost 28% in gastric cancer.
Recent research compared the efficacy of chemotherapy vs best supportive care, combination vs single-agent chemotherapy, and multiple different chemotherapy combinations in advanced gastric cancer.
Post-treatment/preoperative tumor response, as measured on PET, does not predict outcomes in patients with gastric and gastroesophageal junction adenocarcinoma.
Analysis of multiple data sets has helped to elucidate how four recently revealed molecular subsets of gastric cancer might best be managed.
Research in Review
Major complications following total gastrectomy for gastric adenocarcinoma can triple the amount of standard hospital costs.
A routinely available blood test can help improve risk stratification and guide additional therapy for stage II colon cancer.
A higher dose treatment for a type of metastatic gastric adenocarcinoma showed equivalent efficacy and safety.
A recent study showed that over 65% of cases of a certain tumor type were over-diagnosed or inaccurately risk-stratified.
Clinical Pathways for Advance Stage Gastric Cancer: Standardizing Practice to Decrease Variability and Improve Outcomes
In this paper, the author reviews the treatment options for advanced stage gastric cancer and discusses how clinical pathways have the potential to standardizing treatment and improve outcomes for patients with this disease.